Key result
Combining aspirin with clopidogrel or glycoprotein IIb/IIIa antagonists represents an emerging trend in platelet inhibition.
Why the study?
With the advent of newer invasive techniques and potent antiplatelet agents, antiplatelet therapy was poised to change and diversify beyond standard aspirin.
Answers are grounded in this paper and cite their sources.
The landscape of antiplatelet therapy is diversifying beyond aspirin monotherapy to include dual antiplatelet combinations and glycoprotein IIb/IIIa antagonists.
For many years, aspirin has set the standard for platelet inhibition in cardiovascular prophylaxis and therapy. With the advent of newer, invasive techniques and new potent antiplatelet agents, antiplatelet therapy will be likely to change and diversify in the near future. This brief review summarises present and future developments. Essentially, two trends are crystallizing: (a) the combination of established antiplatelet agents such as aspirin with ticlopidin or newly with others such as clopidogrel and (b) the platelet glycoprotein 11b/IIIa antagonists in their different, optimized molecular forms and dosages.
No takes yet. Share an insight, caveat, or question.
Beer et al. (1998) studied this question. Combining aspirin with agents like clopidogrel or using platelet glycoprotein IIb/IIIa antagonists represents emerging trends in platelet inhibition therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: